ORIC Pharmaceuticals Crecimiento futuro
Future controles de criterios 0/6
Se prevé que los beneficios de ORIC Pharmaceuticals disminuyan en un 5.4% al año, mientras que se espera que sus ingresos anuales crezcan en un 47.8% al año. Se prevé que el BPA crezca en un 3.4% por año. Se espera que la rentabilidad financiera sea de -46.2% en 3 años.
Información clave
-5.4%
Tasa de crecimiento de los beneficios
3.4%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs | 23.2% |
Tasa de crecimiento de los ingresos | 47.8% |
Rentabilidad financiera futura | -46.2% |
Cobertura de analistas | Good |
Última actualización | 18 Apr 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains
Mar 13We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate
Jan 18We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Sep 27ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 14Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
Jan 24ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech
Oct 14Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?
Oct 08ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09
Aug 11ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 24We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Mar 08We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Nov 23We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Aug 05ORIC Pharmaceuticals EPS beats by $0.04
May 06Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation
Apr 16We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Jan 01Oric Pharma starts expansion phase of mid-stage solid tumor study with ORIC-101
Dec 21Oric Pharma prices stock offering at $23
Nov 13Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2026 | 14 | -167 | -149 | N/A | 7 |
12/31/2025 | N/A | -148 | -108 | -106 | 8 |
12/31/2024 | N/A | -123 | -78 | -78 | 9 |
12/31/2023 | N/A | -101 | -87 | -86 | N/A |
9/30/2023 | N/A | -93 | -78 | -77 | N/A |
6/30/2023 | N/A | -93 | -78 | -76 | N/A |
3/31/2023 | N/A | -90 | -75 | -73 | N/A |
12/31/2022 | N/A | -89 | -77 | -75 | N/A |
9/30/2022 | N/A | -91 | -78 | -76 | N/A |
6/30/2022 | N/A | -85 | -71 | -69 | N/A |
3/31/2022 | N/A | -85 | -69 | -67 | N/A |
12/31/2021 | N/A | -79 | -60 | -60 | N/A |
9/30/2021 | N/A | -84 | -62 | -61 | N/A |
6/30/2021 | N/A | -91 | -59 | -59 | N/A |
3/31/2021 | N/A | -81 | -53 | -52 | N/A |
12/31/2020 | N/A | -74 | -46 | -45 | N/A |
9/30/2020 | N/A | -54 | -35 | -35 | N/A |
6/30/2020 | N/A | -35 | -31 | -30 | N/A |
3/31/2020 | N/A | -30 | -27 | -26 | N/A |
12/31/2019 | N/A | -27 | -24 | -24 | N/A |
12/31/2018 | N/A | -21 | -21 | -21 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: ORIC is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: Se prevé que ORIC siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que ORIC siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que ORIC no tenga ingresos el año que viene.
Ingresos de alto crecimiento: Se prevé que ORIC no tenga ingresos el año que viene.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: ORIC se prevé que no sea rentable en 3 años.